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Dear Editor
Tegumentary leishmaniasis is a serious public health problem, since it can 
cause psychological and social impact due to facial disfigurement and scars, which 
generate social stigma and self-deprecation. Therefore, new diagnostic methods 
and treatments are urgently needed1. American Tegumentary Leishmaniasis (ATL), 
which include cutaneous leishmaniasis (CL), difuse CL and mucocutaneous 
leishmaniasis2, is a neglected disease caused by a protozoan named Leishmania. 
Leishmania (Viannia) braziliensis, L. (Leishmania) amazonensis, L. (V.) guyanensis, 
L. (V.) naiffi, L. (V.) shawi and L. (V.) lainsoni are the main species  responsible 
for ATL in the New World3. Clinicians working in tropical areas should be aware 
of the main differential diagnosis of leishmaniasis-like lesions, since ATL can be 
confused with several infections4. Therefore, although diagnosis can sometimes 
rely on clinical- epidemiological criteria, laboratory tests are crucial4. Laboratorial 
diagnosis of ATL depends mainly on parasitological and immunological exams. 
The first is represented by direct microscopy and culture and the second by the 
leishmanin skin test, which in Brazil is named Montenegro Skin Test (MST), based 
on the delayed-type hypersensitivity reaction5. MST is used in field studies and 
bedside ATL diagnosis.  Unfortunately, this technique is no longer used in Brazil. 
This is the reason of this Letter to the Editor. 
For the parasitological examination, scarification, biopsy with impression by 
apposition or aspiration punction of the lesion are required  to obtain  smears, which 
are stained by Giemsa or Panotico and  examined by light microscopy. Therefore, 
direct microscopy is the first choice test, since it is easy to perform and is not 
expensive6, however, the main disadvantage is its subjectivity. Figures 1 and 2 
show the images of two smears of samples containing amastigotes, examined 
by microscopy. Figure 1 shows that the identification of six amastigotes is easily 
accomplished, but in Figure 2 it is not easy to define whether the morphological 
aspect is of one amastigote.  Usually, diagnostic difficulties may be related to the 
presence of few parasites in the sample, poor Giemsa or panotico staining quality or 
even to the subjectivity of the technician who examined the slide. Another problem 
is that the microscopic examination, although being cost-effective, is cumbersome 
in terms of the time expent to  examine the whole smear by microscopy, which can 
take sometimes 1 h or more. Another drawback microscopy is the huge sensitivity 
variability, from 15 to 70%7-9.  Parasitological examination also include culture 
techniques in NNN medium (McNeal, Novy, Nicolle) enriched with Liver infusion 
triptose (LIT).  After a period of five days, it is possible to find promastigotes by 
microscopy, leading to the etiological confirmation (gold standard). Conventional 
culture sensitivity may vary between 40 to 75%7,10. However, the main disadvantage 
of cultures is contamination, which is very common11. 
Molecular biology tecniques are promising tools, but they are expensive. 
Depending of the chosen target the reaction can present a high sensitivity and 
specificity and enabling species definition. Polymerase chain reaction has quickly 
emerged as the molecular diagnostic method of choice because it rapidly provides 
reliable speciation, with sensitivity around 97% to 100%2. However, mainly due 
to the lack of standardization, they are not considered the gold standard for ATL 
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diagnosis and their use is limited by the need of specialized 
centers6.
Serological tests like IFI (Indirect Immunofluorescence) 
and ELISA (Enzyme Immunoassay) are recommended 
for mucosal leishmaniasis, but in general, they are 
not sufficiently sensitive for cutaneous leishmaniasis 
diagnosis12. 
Considering all that has been commented,the main 
immunological test for CL should be the Montenegro Skin 
Test (MST). It is an allergic reaction translating a delayed 
cellular hypersensitivity response. MST was introduced 
in 1926 by Montenegro to diagnose ATL with favorable 
clinical applicability and low cost13. MST is performed 
according to established protocols: after an intradermal 
injection of  0,1 mL (the standard volume used) of the 
antigen (phenol-killed promastigotes) in the patient forearm 
indurations are measured  after 48 or 72 h. Induration of 
5 mm and greater are considered as positive results. MST 
presents high predictive value, being positive in more than 
90% of ATL cases3 with high sensitivity and specificity. 
According to Guedes et al.5, it is important to bear in 
mind that MST is an easy method to perform, with low 
cost, does not require sophisticated equipment, and can 
be performed in loco. Provided by the CPPI - Centro de 
Produção e Pesquisa de Imunobiológicos (Immunobiology 
Production and Research Center), located in Parana State, 
Southern Brazil, the production of Montenegro antigen 
available in Brazil had been authorized and inspected 
by ANVISA - Agência Nacional de Vigilância Sanitária 
(National Health Surveillance Agency)5. Anvisa is a 
regulatory agency, belonging to the Brazilian Ministry 
of Health. Regarding MST, Goto and Lindoso12, showed 
that the positivity of MST in CL patients varies from 
82 to 89%, while in mucosal leishmaniasis and difuse 
leishmaniasis, positivity is usually 100%. Pontello Jr. et 
al.14, studying an epidemiological profile of American 
cutaneous leishmaniasis in Londrina, Parana State, 
from 1998 to 2009, showed a positivity of 84.4% using 
MST. According to Krolewiecki et al.15, MST is a useful 
diagnostic complement for the diagnosis of ATL and Tirelli 
et al.4, included it as one of the main complementary exams 
necessary to the final diagnosis of ATL. Granjeiro Jr. et al.16 
compared ATL diagnostic methods and observed that 27.3% 
of the cases were diagnosed by histopathological methods, 
37.7% by imprint, 46.3% by MST, 22% by culture and 
33.1% by immunohistochemistry. Thus, MST was more 
sensitive in comparison with other methods. Sensitivity 
of MST presented in the study of Krolewiecki et al.15 is 
in accordance with previous studies, all of them reporting 
sensitivities ≥ 90%17,18. Therefore, MST is indicated for 
ATL diagnosis since it demonstrates high sensitivity, 
according to the previously mentioned studies. In addition, 
it is  affordable. For a neglected disease such as ATL, MST 
is important mainly to remote and poor cities of Brazil, 
with high ATL endemicity. Thus, why the production of 
MST antigen was discontinued? During the 53rd Congress 
of the Brazilian Society of Tropical Medicine / Meeting 
in Applied Research in Chagas and Leishmaniasis,  held 
in August 27 to 30, 2017, in the city of Cuiaba, Mato 
Grosso State, Brazil, it was announced that ANVISA had 
required some changes in CCPPI infrastructure regarding 
the production of MST antigen.  According to ANVISA, 
an infrastructure similar to the ones of vaccines production 
would be necessary in CCPPI. Faced with this demands, 
CPPI  suspended the production of MST antigen. We all 
agree that a rigorous  quality control is imperative during the 
production of MST. However, following the MST antigen 
suspension by CPPI, it was no longer possible to use MST 
for ATL diagnosis and an explanation should be given to the 
communities and the physicians, who need to diagnose and 
treat patients with ATL. Most of the time, they have no other 
options to get to ATL diagnosis, as some of them stated at 
Figure 1 - Presence of six amastigotes of Leishmania on 
the smear stained by Panotico, from sample of patient with 
leishmaniasis.
Figure 2 - Presence of one amastigote of Leishmania on 
the smear stained by Panotico, from sample of patient with 
leishmaniasis.
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the 53º Congress.  As previously mentioned, parasitological 
examination presents non-negligible limitations. Therefore, 
it is necessary to give an answer to the general public and 
in particular to the patients, who are suffering without 
diagnosis and treatment, not forgetting their doctors.  After 
all, how long will the suspension of the MST antigen by 
CPPI last? How will the Brazilian Ministry of Health solve 
this problem? What has been done?  It took a long time 
before the Institute of Technology in Immunobiology, Rio 
de Janeiro State, and the Butantã Institute, Sao Paulo State, 
had the infrastructure for vaccines production. Therefore, 
why did they not take over the production of the MST 
antigen?  Will American Tegumentary Leishmaniasis be a 
permanently neglected disease? Why? It is necessary to take 
the role of MST in the context of ATL, seriously. I believe 
that this is named responsibility and empathy with patients 
and their doctors. 
Lucia Maria Almeida Braz 1
REFERENCES
 1.  Bennis I, Belaid L, De Brouwere V, Filali H, Sahibi H, Boelaert 
M. The mosquitoes that destroy your face: social impact 
of cutaneous leishmaniasis in South-eastern Morocco, a 
qualitative study. PLoS One. 2017;12:e0189906.
 2.  Kevric I, CappeI MA, Keeling JH. New World and Old World 
Leishmania infections: a practical review. Dermatol Clin. 
2015;33:579-93.
 3.  Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. 
Departamento de Vigilância das Doenças Transmissíveis. 
Manual de vigilância da leishmaniose tegumentar. Brasilia: 
Ministério da Saúde;  2017. [cited 2019 Feb 11]. Available 
from: http://bvsms.saude.gov.br/bvs/publicacoes/manual_
vigilancia_leishmaniose_tegumentar.pdf
 4.  Tirelli F, Vernal S, Roselino AM. Final diagnosis of 86 cases 
included in differential diagnosis of American tegumentary 
leishmaniasis in a Brazilian sample: a retrospective cross-
sectional study. An Bras Dermatol. 2017;92:642-8.
 5.  Guedes DC, Minozzo JC, Pasquali AK, Faulds C, Soccol CR, 
Thomaz-Soccol V. New strategy to improve quality control 
of Montenegro skin test at the production level. Rev Soc Bras 
Med Trop. 2017;50:788-94.
 6.  Gomes CM, Paula NA, Morais OO, Soares KA, Roselino AM, 
Sampaio RN. Complementary exams in the diagnosis of 
American Tegumentary leishmaniasis. An Bras Dermatol. 
2014:89;701-9. 
 7.  Reis LC, Brito ME, Almeida EL, Félix SM, Medeiros AC, Silva 
CJ, et al. Clinical, epidemiological and laboratory aspects of 
patients with American cutaneous leishmaniasis in the State 
of Pernambuco. Rev Soc Bras Med Trop. 2008;41:439-43.
 8.  Boggild AK, Ramos AP, Espinosa D, Valencia BM, Veland 
N, Miranda-Verastegui C, et al. Clinical and demographic 
stratification of test performance: a pooled analysis of five 
laboratory diagnostic methods for American cutaneous 
leishmaniasis. Am J Trop Med Hyg. 2010;83:345-50.
 9.  Szargiki R, Castro EA, Luz E, Kowalthuk W, Machado 
AM, Thomaz-Soccol V. Comparison of serological and 
parasitological methods for cutaneous leishmaniasis diagnosis 
in the state of Paraná, Brazil. Braz J Infect Dis. 2009;13:47-52. 
 10.  Ameen M. Cutaneous leishmaniasis: advances in disease 
pathogenesis, diagnostics and therapeutics. Clin Exp Dermatol. 
2010;35:699-705.
11.  Godoy NS, Andrino ML, Souza RM, Gakiya E, Amato VS, 
Lindoso JA, et al. Could kDNA-PCR in peripheral blood 
replace the examination of bone marrow for the diagnosis of 
visceral leishmaniasis? J Parasitol Res. 2016;2016:1084353.
 12.  Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous 
and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther. 
2010; 8:419-33. 
 13.  Skraba CM, Mello TF, Pedroso RB, Ferreira EC, Demarchi IG, 
Aristides SM, et al. Evaluation of the reference value for the 
Montenegro skin test. Rev Soc Bras Med Trop. 2015;48:437-
44.
 14.  Pontello Jr R, Gon AS, Ogama A. American cutaneous 
leishmaniasis: epidemiological profile of patients treated in 
Londrina from 1998 to 2009. An Bras Dermatol. 2013;88:748-
53.
 15.  Krolewiecki AJ, Almazan MC, Quilpildor M, Juarez M, Gil JF, 
Espinosa M, et al. Reappraisal of Leishmanin Skin Test (LST) 
in the management of American Cutaneous Leishmaniasis: a 
retrospective analysis from a reference center in Argentina. 
PLoS Negl Trop Dis. 2017;11:e0005980.
 16.  Granjeiro Jr CR, Pimentel JV, Teixeira Jr AG, Jesus AF, Galvão 
TC, Souza LA, et al. American cutaneous leishmaniasis in a 
northeast Brazilian city: clinical and epidemiological features. 
Rev Soc Bras Med Trop. 2018;51:837-42.
 17.  Weigle KA, Valderrama L, Arias AL, Santrich C, Saravia NG. 
Leishmanin skin test standardization and evaluation of safety, 
dose, storage, longevity of reaction and sensitization. Am J 
Trop Med Hyg. 1991;44:260-71.
 18.  Souza WJ, Sabroza PC, Santos CS, Sousa E, Henrique MF, 
Coutinho SG. Montenegro skin tests for American cutaneous 
leishmaniasis carried out on school-children in Rio de 
Janeiro, Brazil: an indicator of transmission risk. Acta Trop. 
1992;52:111-9.
